Market Overview

UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects

Related BMY
Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
These Were The Most And Least Popular Stocks In September
Here's How Lilly And Merck Are Faring In The Cancer Drug Wars: Earnings Out Next Week (Seeking Alpha)

Jefferies maintained Bristol-Myers Squibb (NYSE: BMY) with a Buy rating and raisd the price target from $39.00 to $41.00.

Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing meaningful earnings momentum, whilst several major R&D catalysts (anti-PD1 and Yervoy) further expand the PE multiple. We reiterate our Buy rating and have increased our PT to $41 (from $39)."

Bristol-Myers Squibb closed at $36.93 on Monday.

Latest Ratings for BMY

Oct 2016Credit SuisseMaintainsNeutral
Sep 2016CitigroupMaintainsBuy
Sep 2016JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!